BTIG, Inari
In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Globus Medical (GMED – Research Report), with a price target of ...
Jonathan Krinsky, chief market technician at BTIG, joins CNBC's 'The Exchange to discuss his outlook on stocks for 2025, what ...
BTIG analyst Thomas Shrader lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $35 and keeps a Buy rating on the shares after the company announced topline data from the Phase 2 ...
BTIG Research has recently reduced Fiverr International Ltd (FVRR) stock to Neutral rating, as announced on November 4, 2024, according to Finviz. Earlier, on July 2, 2024, UBS had reduced the stock ...
The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...
BTIG Chief Market Technician Jonathan Krinsky thinks the market can “continue to make upside progress” into year-end and sees a new all-time high for the S&P 500 (SPX) above 6,100. However ...
FiscalNote Holdings Inc (NOTE) stock saw a decline, ending the day at $1.33 which represents a decrease of $-0.04 or -2.92% from the prior close of $1.37. The stock opened at $1.45 and touched a low ...
BTIG raised the firm’s price target on Glaukos (GKOS) to $157 from $149 and keeps a Buy rating on the shares as part of a broader research note updating the firm’s models on Medical Technology names ...
BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...
BTIG Research has recently reduced Beyond Air Inc (XAIR) stock to Neutral rating, as announced on June 25, 2024, according to Finviz. Earlier, on July 28, 2023, Piper Sandler had initiated the stock ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback